IDEMIA
IDEMIA, the global leader in Augmented Identity, and Nationwide Building Society, the world’s largest building society, both undertake to promote greener financial services. From 2021, new IDEMIA-sourced cards made from recycled plastic will be rolled out in the UK.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201105005086/en/
At a time when environmental issues increasingly take center stage, IDEMIA will join forces with Nationwide Building Society to deliver cards made from recycled PVC that will slash the bank’s carbon footprint without compromising on security or end user convenience.
With Nationwide’s 5.4 million new plastic payment cards every year, this alliance aims to save 35 metric tons of carbon annually - production of one card will save 7 grams of carbon compared to a standard PVC payment card. By using recycled PVC sourced from printing and packaging industrial waste, IDEMIA’s solutions slash plastic waste, which significantly reduces carbon emissions. It also helps to reduce landfill space, energy consumption as well as land and water pollution.
Nationwide will introduce cards made using recycled plastics from early spring next year and is the first high street lender to commit to do so. The environmentally-friendly cards will be issued to current account members first, before “the Society” rolls out the cards across its product range. Nationwide pledges to eliminate single-use plastics by 2025.
This alliance reinforces IDEMIA’s determination to bring about change in the financial services industry. It forms part of GREENPAY™, IDEMIA’s eco-friendly all-embracing package deal for financial institution customers around the world.
IDEMIA’s Executive VP Financial Institutions Amanda Gourbault said: “IDEMIA is proud to be a long term partner of Nationwide Building Society and delighted to support Nationwide’s sustainability goals with IDEMIA’s recycled plastics payment card product. This type of card is manufactured from waste materials and as such significantly reduces plastic waste, one of the most pressing problems of our modern world. Migrating to recycled plastics is also beneficial as it saves energy, limits oil consumption and reduces greenhouse gas emissions, to help mitigate global warming and reduce air pollution. At IDEMIA, we take sustainable development very seriously and we are using our expertise to create and promote more responsible and environmentally friendly solutions through GREENPAY, our portfolio of sustainable solutions for financial institutions and FinTechs . Nationwide’s decision to provide its members with eco-friendly PVC cards from IDEMIA confirms our objective to provide green solutions that help protect our planet – because banking cards shouldn’t cost the earth”.
Claire Tracey, Chief Strategy and Sustainability Officer at Nationwide Building Society added : “We’re proud to be the first high street lender in the UK to offer cards made from recycled plastics. Our members tell us that, despite the tough times right now, they still want to make the world a greener place. Earlier this year we became carbon neutral for energy and emissions for all internal operations and Society vehicles. We’ve also set aside £1 billion for our members to borrow at a special low interest rate if they want to make their homes greener. Today’s news is another step for us in helping the UK to achieve net-zero by 2050 and a significant step in us eliminating single-use plastics by 2025.”
IDEMIA is a leader in innovative solutions that meet user needs in the rapidly changing financial services industry landscape. They offer financial institutions a complete and innovative portfolio of solutions ranging from classic EMV card technologies, eye-catching metal cards, to cutting-edge mobile payment, digital services and innovative online payment security.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20201105005086/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom